Opus Genetics Appoints Dr. Andrew Murphy as Chief Scientific Officer and Jamie Lynne Hart as Executive Director, Executive Operations
Opus Genetics appointed Andrew Murphy, Ph.D., as Chief Scientific Officer and Jamie Lynne Hart as Executive Director, Executive Operations. Dr. Murphy brings 18+ years of gene therapy and AAV vector development experience, most recently as SVP of Research at Kriya Therapeutics; Hart spent 15+ years in biotech operations including at Apellis and Ocular Therapeutix.
Key figures
- Pipeline programs
- 7
- New ed experience years
- 15+
- New cso experience years
- 18+
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.